Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Domestic sales increased 15.5%, supported by the relaunch of previously recalled products in the market
For the fourth quarter, revenue surged 47% year-on-year to Rs. 2,510 million, driven by a 23% rise in domestic sales and a 9.3x jump in export sales
HCG clinicians contributing to one of the largest bodies of oncology research from India
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Stable profits, low leverage to keep credit profiles comfortable
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
The company sees the business reaching $100mn
Subscribe To Our Newsletter & Stay Updated
